Literature DB >> 21978715

Nonclassical major histocompatibility complex I-like Fc neonatal receptor (FcRn) expression in neonatal human tissues.

Corina Cianga1, Petru Cianga, Petru Plamadeala, Cornelia Amalinei.   

Abstract

The neonatal Fc receptor (FcRn) was demonstrated to play a role both in the recycling and thus the protection of immunoglobulin G (IgG) from catabolism and in the maternal-fetal transfer of IgG. The expression of this particular receptor was evidenced in a variety of cell types, but the endothelial cell was considered the main cell able to perform both recycling and IgG catabolism. Based on preliminary data obtained in adult human mammary glands and skin, this study focused on a number of neonatal human tissues, targeting FcRn expression mainly in epithelial versus endothelial cells. Our results demonstrate that in most of the investigated tissues, the neonatal Fc receptor is not detectable in the endothelial cells lining the capillaries, whereas most epithelial cells are positive. We could also observe the receptor's expression in most macrophages, smooth muscle cells, and neurons. Taken together, these data suggest that the main sites of IgG catabolism might in fact be other than endothelial cells in human neonates.
Copyright © 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978715     DOI: 10.1016/j.humimm.2011.08.020

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  The neonatal Fc receptor is a pan-echovirus receptor.

Authors:  Stefanie Morosky; Alexandra I Wells; Kathryn Lemon; Azia S Evans; Sandra Schamus; Christopher J Bakkenist; Carolyn B Coyne
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

Review 2.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

Review 3.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Authors:  Jonathan T Sockolosky; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2015-02-19       Impact factor: 15.470

4.  The effect of the neonatal Fc receptor on human IgG biodistribution in mice.

Authors:  Nancy Chen; Weirong Wang; Scott Fauty; Yulin Fang; Lora Hamuro; Azher Hussain; Thomayant Prueksaritanont
Journal:  MAbs       Date:  2014-01-09       Impact factor: 5.857

5.  Localization of the human neonatal Fc receptor (FcRn) in human nasal epithelium.

Authors:  Sara Heidl; Isabella Ellinger; Verena Niederberger; Eva E Waltl; Renate Fuchs
Journal:  Protoplasma       Date:  2015-12-03       Impact factor: 3.356

6.  Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.

Authors:  Paul R V Malik; Abdullah Hamadeh; Andrea N Edginton
Journal:  Pharm Res       Date:  2022-02-03       Impact factor: 4.200

Review 7.  HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn.

Authors:  Isabella Ellinger; Renate Fuchs
Journal:  Wien Med Wochenschr       Date:  2012-05

8.  Peripheral Dendritic Cells and CD4+CD25+Foxp3+ Regulatory T Cells in the First Trimester of Normal Pregnancy and in Women with Recurrent Miscarriage.

Authors:  Maciej Kwiatek; Tomasz Gęca; Arkadiusz Krzyżanowski; Agnieszka Malec; Anna Kwaśniewska
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

9.  FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues.

Authors:  Tommy Li; Joseph P Balthasar
Journal:  Biomolecules       Date:  2018-10-15

10.  A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.

Authors:  Hsuan Ping Chang; Valentina Shakhnovich; Adam Frymoyer; Ryan Sol Funk; Mara L Becker; K T Park; Dhaval K Shah
Journal:  Br J Clin Pharmacol       Date:  2021-07-19       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.